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Abstract
Intercellular junctions promote homotypic cell to cell adhesion and transfer intracellular signals which control cell growth
and apoptosis. Junctional adhesion molecule-A (JAM-A) is a transmembrane immunoglobulin located at tight junctions of
normal epithelial cells of mammary ducts and glands. In the present paper we show that JAM-A acts as a survival factor for
mammary carcinoma cells. JAM-A null mice expressing Polyoma Middle T under MMTV promoter develop significantly
smaller mammary tumors than JAM-A positive mice. Angiogenesis and inflammatory or immune infiltrate were not
statistically modified in absence of JAM-A but tumor cell apoptosis was significantly increased. Tumor cells isolated from
JAM-A null mice or 4T1 cells incubated with JAM-A blocking antibodies showed reduced growth and increased apoptosis
which paralleled altered junctional architecture and adhesive function. In a breast cancer clinical data set, tissue microarray
data show that JAM-A expression correlates with poor prognosis. Gene expression analysis of mouse tumor samples
showed a correlation between genes enriched in human G3 tumors and genes over expressed in JAM-A +/+ mammary
tumors. Conversely, genes enriched in G1 human tumors correlate with genes overexpressed in JAM-A2/2 tumors. We
conclude that down regulation of JAM-A reduces tumor aggressive behavior by increasing cell susceptibility to apoptosis.
JAM-A may be considered a negative prognostic factor and a potential therapeutic target.
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Introduction
JAM-A (Junctional adhesion molecule-A) is a small immuno-
globulin expressed by different cell types including epithelial,
endothelial cells, leukocytes, dendridic cells and platelets [1,2,3,4].
Several studies, using blocking antibodies or genetically modified
mice, documented a role of JAM-A in mediating neutrophil and
monocyte infiltration in different experimental inflammatory
conditions such as peritonitis, meningitis, liver and heart ischemia
and others [1,2,3,5,6]. The mechanism of action of JAM-A in
inflammation is complex and may be different depending on the
cellular context.
In epithelial cells JAM-A is preferentially concentrated at tight
junctions and cooperates with claudins in promoting cell to cell
adhesion. In absence of JAM-A colonic mucosa epithelial cells
looses permeability control, favoring inflammatory colitis [7,8].
The role of JAM-A in tumor growth and dissemination is still a
debated issue. In a recent work, we have crossed Rip1Tag2 mice
(pancreatic islet tumor mouse model) with JAM-A null mice.
Rip1Tag2 mice develop pancreatic tissue hyperplasia and highly
vascularized adenoma which progress to invasive carcinoma [9].
In this particular model, tumor cells do not express JAM-A which
is however present in the cells of the stroma. We observed a
significant reduction of growth in JAM-A null mice due to
increased immunological response of the host and decrease in
angiogenesis. Conflicting data have been published on the role of
JAM-A in breast cancer. Naik MU et al. [10] reported that JAM-A
expression reduces breast cancer cell lines’ invasion and motility in
vitro and is inversely related to carcinoma aggressiveness and
metastatic behavior in human patients. In contrast, McSherry et
al. [11] using a larger clinical data set showed that JAM-A
expression is a negative prognostic factor in breast cancer.
In the present paper we tackled the problem of the role of JAM-
A in breast cancer by applying different experimental and
complementary approaches. We examined mammary tumor
growth and dissemination in JAM-A null mice crossed with mice
expressing a mutant form of Polyoma virus middle T (PyVmT)
under mammary tumor virus promoter (MMTV) [12]. We used
tumor cells freshly isolated and cultured from MMTV-PyVmT
mouse tumors or 4T1 mammary tumor cell line to understand the
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group of human patients, whether JAM-A expression negatively or
positively correlates with breast cancer progression.
Taken together data show that in absence of JAM-A tumors
grow significantly less in MMTV-PyVmT mice. Consistently, we
found an inverse correlation between JAM-A expression and
cancer prognosis in human patients. In vivo studies of MMTV-
PyVmT tumors and in vitro experiments on cultured tumor cells
show that abrogation of JAM-A expression or function causes
tumor cell apoptosis. This effect parallels altered organization of
intercellular cell to cell junctions and may explain the decrease in
tumor growth observed in absence of JAM-A.
Materials and Methods
Ethics Statement
Written informed consent for research use of biological samples
was obtained from all patients, and the research project was
approvedbytheInstitutionalEthicalCommittee.CurrentMembers
of the IEO Ethics Committee: Luciano Martini (Chairman),
Director of the Institute of Endocrinology, Milan; Apolone
Giovanni (Vice Chairman), Chief of the Translational and
Outcome Research Laboratory and the ‘‘Mario Negri’’ Institute,
Milan; Bonardi Maria Santina, Head of the Nursing Service of
European Institute of Oncology, Milan; Cascinelli Natale, Scientific
Director of National Cancer Institute, Milan; Gallus Giuseppe,
Director of Institute of Medical Statisticsof Milan; Gastaldi Stefano,
Psychologist and Psychotherapist, Scientific Director of Attiveco-
meprima; Goldhirsch Aron, Director of the Department of
Medicine of European Institute of Oncology, Milan; La Pietra
Leonardo, Chief Medical Officer of European Institute of
Oncology, Milan; Loi Umberto, Export in Legal Procedures,
Monza; Martini Luciano (Presidente), Director - Institute of
Endocrinology, Milan; Merzagora Francesca, President of Italian
Forum of Europa Donna,Milan; OmodeoSale Emanuela,Director
of Pharmaceutical Service, European Institute of Oncology, Milan;
Pellegrini Maurizio, Head of the Local Health District, Milan;
Rotmensz Nicole, Head of the Quality Control Unit, European
Institute of Oncology, Milan; Tomamichel Michele, Director,
Sottoceneri Sector Cantonal Sociopsychiatric Organisation, Lu-
gano; Monsignor Vella Charles, Bioethicist and theologist, S.
Raffaele Hospital and Scientific Institute, Milan; Veronesi Um-
berto, Scientific Director, European Institute of Oncology, Milan.
OBSERVERS: Ciani Carlo, Chief Executive Officer, European
Institute of Oncology, Milan; Della Porta Giuseppe, Research Co-
ordinator, European Institute of Oncology, Milan; Michelini
Stefano, Managing Director, European Institute of Oncology,
Milan. SECRETERIAT OFFICE: Nonis Atanasio (head), Con-
trolled Clinical Studies Office, European Institute of Oncology,
Milan; Tamagni Daniela (Assistant), Controlled Clinical Studies
Office, European Institute of Oncology, Milan.
Tissue Samples
Formalin fixed and paraffin embedded specimens were
provided by the Pathology Departments of the European Institute
of Oncology (Milan).
Animal statement. Mice were housed according to the
guidelines set out in Commission Recommendation 2007/526/
EC - June 18, 2007 on guidelines for the accommodation and care
of animals used for experimental and other scientific purposes. At
the end of the experiment, mice were euthanized by inhalation of
high concentrations of CO2. Currently, the Italian legislation does
not require a specific ethical review process for all the experiments
involving animals.
Mammary Tumor and Lung Metastases
MMTV-PyVmT transgenic mice, a spontaneous mouse model
of breast tumor were generated by WJ. Muller (McKMaster
University, Ontario, Canada) [12] and provided by G. Christofori
(University of Basel, Basel, Switzerland). They were crossed with
JAM-A2/2 mice to obtain a MMTV-PyVmT/JAM-A2/2
strain. MMTV-PyVmT/JAM-A+/+ littermates were used as
control. Mice were palpated twice a week and tumor appearance
was recorded. Tumor-free survival was calculated from Kaplan–
Meier curves and statistical significance was determined by the
Log-Rank test for the survival studies and t-test for tumor growth
studies. The metastatic ratio was evaluated by removing the lungs
from anesthetized mice and inspecting metastatic nodules on the
lung surface by using a stereoscope (Nikon SMZ800 stereoscope
63–5, Tokyo, Japan) as described [13]. Tumor weight and lung
metastasis logistic curve was made by JMP software (SAS Institute,
Cary, North Carolina) and analyzed by Fisher’s test.
Immunofluorescence, Image Quantitative Analysis and
Western blot
For the immune phenotypical characterization of MMTV-
PyVmT/JAM-A+/+ and JAM-A2/2 mice, tumor and lung
samples or cultured cells were fixed in 4% paraformaldehyde or
methanol for 24 h, and kept at 4uC in phosphate buffer saline
(PBS) until use. 10 mm tissue sections and cell specimens were
stained as previously reported [9,14] using the following
antibodies: CD4, CD8, CD11c, MHC-II, b-catenin (BD Biosci-
ence, San Jose, CA), F4/80 (Serotec, Kidlington, UK), PECAM-1
(clone Mec13.3 or Millipore, Billerica, MA), Ki-67 (Abcam,
Cambridge, MA), E-cadherin (Invitrogen, Carlsbad, CA), ZO-1,
Cingulin (Zymed/Invitrogen, Carlsbad, CA), JAM-A (clone
BV12), b1-integrin (Chemicon, Billerica, MA). TdT-mediated
dUTP nick end labeling (TUNEL) staining was done using the In
Situ Cell Death Detection Kit (Roche, Basel, Switzerland).
Samples were analyzed under an AX-70 Provis (Olympus,
Hamamatsu, Japan) fluorescence microscope equipped with a
black and white cooled CCD camera (c5985, Olympus), or with a
Leica TCS SP2 AOBS confocal microscope equipped with 405,
488, 543, and 633 nm laser lines (Wetzlar, Switzerland). Digital
images were computer processed with Adobe Photoshop CS2
(Adobe Systems Inc, San Jose, CA). For the quantitative analysis of
immunofluorescence experiments ImageJ image-analysis software
(W. Rasband, National Institutes of Health) was used to measure
the specific mean intensity on an average of ten cells for each
antibody staining. Background intensity was initially subtracted by
placing ‘‘regions of interest’’ over areas devoid of specific signal.
For Western blot analysis cells were lysed in Tris-buffer saline
containing 0.1% Tween-20 (T-TBS) and 1% Triton X-100. Cell
lysates were resolved by SDS-PAGE and transferred to nitrocel-
lulose membranes (Millipore, Billerica, MA). Proteins of interest
were visualized using specific antibodies, JAM-A (clone BV12/
BV19/BV20), E-cadherin, (BD Bioscience), b1-integrin, ZO-1
(Cell signaling, Boston, MA), and a ´-tubulin (Sigma, St Louis,
MO), followed by peroxidase-conjugated secondary antibodies
and by an enhanced chemiluminescence kit (Amersham Biosci-
ences, Little Chalfort, UK).
Cell Culture
4T1 mouse mammary tumor cells were obtained from the
American Type Culture Company (Manassas, VA) and were
cultured in RPMI 1640 medium (Gibco/Invitrogen, Carlsbad,
CA) supplemented with 10% fetal bovine serum plus 1.0 mM
sodium pyruvate, and 100 U/ml penicillin, and 100 mg/ml
JAM-A and Mammary Carcinoma
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endothelial cells were isolated from the lung microcirculation and
cultured as described [16]. To obtain primary tumor cells, late
stage tumors (14–16 week old) from MMTV-PyVmT/JAM-A+/+
and JAM-A2/2 females were harvested and minced using a
razor blade, then digested using collagenase/hyaluronidase
solution (Stem Cell Technologies, Vancouver, Canada) at 37uC
for 2 hour. The samples were washed with 5 volumes of HBSS
(Sigma)+2% fetal bovine serum and 2 mmol/L ethylenediamine-
tetraacetic acid (EDTA) (HFE) and centrifuged at 4506g for
5 min. The pellet was dissociated in 5 mL Trypsin-EDTA, then
2 mL dispase (Stem Cell Technologies): for 1 and 3 min
respectively, by continuous pippetting, diluted with 10 mL HFE,
and passed through a 40 mm cell strainer to obtain single-cell
suspension. Isolation of epithelial cells was achieved through
selective depletion of hematopoietic, endothelial, and stromal cells
using a Mouse Epithelial Cell Enrichment Kit (Stem Cell
Technologies). Briefly, the single-cell suspension was concentrated
to1610
8 cells/mL. Biotinylated antibodies (0.5 mg per million
cells) against stromal cells (CD140a, eBiosciences, San Diego, CA),
endothelial cells (PECAM-1), and hematopoietic cells (CD45 and
TER119) were added for 15 min at 4uC. Antibody conjugation to
magnetic nanoparticles was achieved through 15-min incubation
with EasySep Biotin Selection cocktail followed by 10 min with
EasySep Magnetic Nanoparticles. An EasySep Magnetic device
was used for 5 min to separate the non-epithelial cells that
attached to the tube surface from the epithelial cells that remained
in the supernatant. Mammary primary cells were cultured in 5%
FBS and 10 ng/ml Epidermal Growth Factor (EGF) (Stem Cell
Technologies), 10 ng/ml Fibroblast Growth Factor (FGF) and
4 mg/ml heparin containing complete EpiCult-B medium (Stem
Cell Technologies). Non-attached cells and debris were flushed
away the second day and the remaining cells were cultured in
cytokine containing complete EpiCult-B medium.
Cell Proliferation
4T1 cells were seeded and incubated for 24 hours in complete
medium, followed by an overnight incubation in 10% FBS
containing complete medium or in serum-free medium for 24, 48
or 72 hours. This was followed by fixation and staining with crystal
violet. Stained cells were then solubilized with 10% acetic acid, and
the 595 nm absorbance was measured for each time point.
Wound Assay
4T1 cells were seeded, grown to confluence and starved
overnight in the presence of 5 mg/ml control rat IgG antibody
or BV11 JAM-A neutralizing antibody containing complete
medium. Confluent monolayers were wounded with a pipette tip
of approximately 1-mm of diameter. Cell monolayers were
incubated with the antibody in complete medium and migration
of 4T1 cells area was monitored by using phase contrast
microscopy.
Calcium Switch Assay
Confluent 4T1 cells were incubated with EGTA (2 mM in
complete medium). 60 min later EGTA was aspirated and cells
were incubated with control or BV11 antibody for 30, 60, and
120 min as described (19). At the end of each period of incubation
cells were fixed and stained with anti E-cadherin antibody.
Tissue-Micro Array (TMA)
All clinical investigation has been conducted according to
Declaration of Helsinki principles. Large-scale TMA of 444
patient breast cancer case–control cohort studies were performed
using human JAM-A antibody (R&D, Minneapolis, MN) as
described [17].
Statistical analysis
Disease-free period according to JAM-A expression was drawn
using the Kaplan Meier method and compared by the Log-rank
test. The correlation between the clinic pathological features of the
tumors and JAM-A expression was evaluated; Odds ratio (OR)
and 95% Confidence Intervals (CI) were obtained from logistic
regression models using the JMP statistical software (SAS Institute,
Inc., Cary, NC). A p value of less than 0.05 was considered to be
statistically significant.
Results
MMTV-PyVmT/JAM-A2/2 mice show decreased primary
breast tumor growth
MMTV-PyVmT mice were interbred with JAM-A wild-type
(MMTV-PyVmT/JAM-A+/+) or null mice (MMTV-PyVmT/
JAM-A2/2) [12,18]. JAM-A was expressed in the normal
epithelium of mammary duct and glands in wild type mice and
expression was maintained in MMTV-PyVmT mammary tumor
cells and in metastatic tumor cells in the lymph nodes and lung
(Figure S1). All MMTV-PyVmT/JAM-A+/+ and MMTV-
PyVmT/JAM-A2/2 mice developed mammary tumors within
12 weeks of age, consistent with previous reports [12]. However,
tumors appeared earlier in MMTV-PyVmT/JAM-A+/+ mice
compared to JAM-A2/2 mice (8.5360.26 weeks and 9.8660.26
weeks respectively; p=0.0048, Log-rank test) (Fig. 1A). At 13
weeks tumor size was significantly smaller in MMTV-PyVmT/
JAM-A2/2 than in MMTV-PyVmT/JAM-A+/+ mice
(5.7960.36 g versus 3.4360.35 g p,0.01) (Fig. 1B left panel).
Lung metastatic ratio (the percentage of mice with metastasis out
of the total number of mice with tumors) was lower in JAM-A2/2
than in JAM-A+/+ mice although the difference did not reach
statistical significance (51.2% versus 30.0% Fisher’s test p=0.091)
(Fig. 1B right panel).
More detailed mathematical analysis of the whole data set was
performed (Fig. 1C). The population (82 mice) was classified for
tumor size in two groups on the basis of the median weight of
tumors (3.55 g): big tumors (above median) and small tumors
(below median), each composed of 41 mice; it was then classified
by expression of JAM-A (31 JAM-A 2/2 mice and 51 JAM-A +/
+ mice) and by incidence of metastasis (55 mice did not develop
metastasis and 27 did).
As expected there is a significant correlation between size of
tumor and development of metastasis (overlap between these two
sets is 23 mice while the expectation from the null hypothesis
would be 13.5, thus leading of an indication of positive correlation
that the Exact Fisher Test rates significant with p,10
25).
Expression of JAM-A positively correlated with tumor size (out
of the 51 JAM-A +/+ mice and 41 having big tumors 30 are in the
overlap of the two sets, for a significance of the correlation with
p,0.034), but there is no significant correlation between
expression of JAM-A (51 mice) and metastasis (27 mice out of
82 mice), the overlap is 18 as shown in the Venn Diagram and the
deviation from the expected 16.8 is not statistically significant
(p=0.368).
Logistic curve of mammary tumor size and metastasis also
shows a positive correlation of tumor size and metastasis, but no
significant correlation between incidence of metastasis and JAM-A
expression (Figure S2). Taken together these results indicate that
JAM-A expression positively correlates with MMTV-PyVmT
JAM-A and Mammary Carcinoma
PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e21242Figure 1. Genetic abrogation of JAM-A expression leads to reduction of mouse mammary tumor growth. A) MMTV-PyVmT/JAMA2/2
mice had longer disease-free time compared to JAM-A+/+ mice; B) 13 week-old MMTV-PyVmT/JAM-A2/2 mice present reduced primary tumor
growth. Bars are means 6 SEM. The lung metastases ratio (the percentage of mice with metastases out of the total number of mice with tumors) was
higher in MMTV-PyVmT/JAM-A+/+ compared to JAM-A2/2 mice but did not reach statistical significance (p=0.091); C) Correlation between JAM-A
expression, tumor size and lung metastases: The population was classified for tumor size in two groups on the basis of the median weight of tumors
(3.55 g): big tumors (above median) and small tumors (below median), each composed of 41 mice; the population was then classified by expression
of JAM-A (31 JAM-A 2/2 mice and 51 JAM-A +/+ mice) and by incidence of metastases (55 mice did not develop metastases and 27 did). C.1) Venn
diagram of Big/Small (above or below median weight) tumors and metastases. There is a significant correlation between size of tumor and
development of metastases (overlap between these two sets is 23 mice while the expectation from the null hypothesis would be 13.5, leading to a
significant positive correlation by Exact Fisher Test with p,10
25). C.2) MMTV-PyVmT/JAM-A+/+ or JAM-A2/2 and Big/Small tumors. Expression of
JAM-A positively correlates with tumor size (out of the 51 JAM-A +/+ mice, 41 show big tumors and 30 are in the overlap of the two sets; significance
of correlation p,0.034). C.3) MMTV-PyVmT/JAM-A+/+ or JAM-A2/2 and metastases. The incidence of metastases is not significantly affected by JAM-
A expression if balanced with tumor size. There is no significant correlation between expression of JAM-A (51 mice) and metastases (27 mice out of 82
mice), the overlap is 18 as shown in the Venn Diagram and the deviation from the expected 16.8 is not statistically significant (p=0.368). All
correlations are referred to a population of 82 animals, p Values are calculated by Exact Fisher Test, null values are the expectations for independent
events.Tables on the right side of panel C summarize the results.
doi:10.1371/journal.pone.0021242.g001
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specifically affected.
JAM-A expression increases tumor cell apoptosis
JAM-A is expressed in mammary tumor vasculature (Figure S1).
We have previously shown that the absence of JAM-A reduced
Rip1Tag2 pancreatic islet tumor size, angiogenesis and inflam-
matory infiltrate [9]. Analysis of MMTV-PyVmT tumors showed
that in absence of JAM-A, tumor cells proliferate slightly less
(27.7362.29% versus 35.662.02, p,0.05) but undergo apoptosis
to higher extent than in the presence of this adhesive molecule
(96.4610.2 versus 63.168.5 cells per mm
2 p,0.05) (Fig. 2A).
Conversely, no statistically significant difference in tumor
angiogenesis (Figure S3A), inflammatory (F4/80 positive cells,
Figure S3B) and immune cell infiltrate (CD11c and MHCII
positive cells) was observed (Figure S3C). The number of CD4+
Figure 2. Abrogation of JAM-A expression increases tumor cell apoptosis. A) Histological examination shows lower cell proliferation and
higher apoptosis in MMTV-PyVmT/JAM-A2/2 as compared to JAM-A+/+ tumors. Right panels show quantification of Ki-67 or TUNEL positive cells.
Data are means +/2 SEM *p,0.05 by unpaired Student’s t test. Scale bar: 100 mm. B) The growth curve of 4T1 cells in the presence of a control (Ctrl)
antibody (Ab) or a JAM-A neutralizing Ab (BV11) was measured in the presence (left upper panel) or absence of fetal bovine serum (FBS) (left lower
panel). Under starving conditions, upon exposure to a JAM-A blocking Ab the total cell number was significantly reduced while the number of
TUNEL-positive cells was increased. Values are means 6 SEM of at least 4 replicates from 3 independent experiments. *p,0.05, **p,0.01 by unpaired
Student-t test.
doi:10.1371/journal.pone.0021242.g002
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PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e21242Figure 3. Inhibition of JAM-A expression and function affects mammary tumor cell morphology and organization of cell-cell
junctions. A) Phase-contrast microscopy of cultured mammary tumor cells derived from MMTV-PyVmT/JAM-A+/+ and JAM-A2/2 tumors. JAM-A+/+
cells formed confluent islands with epithelioid morphology and tight intercellular junctions. In contrast, JAM-A2/2 cells form loosely organized
islands and frequently grow as single cells with spindle shape morphology. Scale bar; 200 mm; B) Immunofluorescence staining of markers of
adherens junctions (E-cadherin, b-catenin) and tight junctions (ZO-1, cingulin). While JAM-A+/+ tumor cells present a continuous junctional staining
of E-cadherin, b-catenin, ZO-1 and cingulin at intercellular contacts, in JAM-A2/2 cells the distribution of these markers was reduced or
discontinuous (arrowhead). Scale bar; 15 mm; C) The effect of BV11 JAM-A blocking Ab on Ca
2+ switch assay. 4T1 cells were incubated with EGTA for
60 min to disrupt E-cadherin junctional localization and Ca
2+ was then added back to the cells to restore E-cadherin staining. In the presence of a
JAM-A blocking Ab BV11 E-cadherin staining was partially inhibited and still largely incomplete up to 120 min. Scale bar; 20 mm; D) 4T1cell migration
was significantly increased by a JAM-A blocking Ab (BV11). Upper panels report phase contrast microscopy of a typical experiment. Scale bar; 500 mm.
Lower panels show a quantification of the distance of migration of the front. Values are means 6 SEM of 4 replicates from a typical experiment out of
3 performed. **p,0.01 by unpaired Student-t test.
doi:10.1371/journal.pone.0021242.g003
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PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e21242Figure 4. JAM-A and junctional proteins’ expression was decreased at the invading tumor edge in vivo and in vitro. A) MMTV-PyVmT/
JAM-A+/+ tumor sections show decreased JAM-A and E-cadherin expression level at the invasive edge as compared to tumor nodules and mammary
duct. Scale bar; 100 mm; B) In tissue sections, TUNEL positive tumor cells were concentrated at the invasive edge of the tumor. Scale bar; 100 mm; C) In
the wound assay (see Fig. 3) cultured MMTV-PyVmT/JAM-A2/2 cells show strong TUNEL staining both at the migrating front and in the distal areas
while JAM-A+/+ cells presented TUNEL staining only at the leading edge. Quantification is reported at the right panel, data are means +/2 SEM of 3
experiments performed in quadruplicates. **p,0.01 by unpaired Student-t test. Scale bar; 300 mm; D) Western blot analysis of JAM-A and ZO-1
expression in 4T1 cells in sparse, sub-confluent, and confluent conditions. Quantification is reported in the right panels. The results are representative
of 3 independent experiments.
doi:10.1371/journal.pone.0021242.g004
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difference did not reach statistical significance.
In vitro incubation of BV11 JAM-A neutralizing Ab [19] with JAM-
A positive 4T1 cell line [15] (Figure S4A) did not change cell
proliferation in complete medium but significantly reduced the cell
number in absence of serum (Fig. 2B and C). In starvation, TUNEL-
positive cells were markedly increased (9.3461.80 versus 16.96
2.75%, p=0.03) (Fig. 2E) suggesting that the decreased number of
cells is due to apoptosis. However, the number of 4T1 cells treated
with BV11mAb was lower already at 48 hours when TUNEL staining
was not yet apparent. It is likely, as shown by others [10,20], that JAM-
A 2/2 cells may detach from the plate before showing signs of
apoptosis or, alternatively, that besides its antiapoptotic activity, JAM-
A is required for correct tumor cell growth.
JAM-A affects MMTV-PyVmT mammary cell morphology
and cell-to-cell junction
We then cultured tumor cells from MMTV-PyVmT/JAM-A+/+
and JAM-A2/2 tumors. JAM-A positive cells show a correct
epithelioid morphology while JAM-A null cells showed spindle or
round shape morphology andweak cell to cell adhesion (Fig. 3A). At
immunofluorescence analysis MMTV-PyVmT/JAM-A2/2 cells
presented partially disorganized adherens junctions with discontin-
uous staining of E-cadherin and b-catenin, and loss of tight junction
markers such as ZO-1 and Cingulin inmany areas of the monolayer
(Fig. 3B). However, no significant change in the total amount of
junctional markers and other adhesive and cytoskeletal proteins (E-
cadherin, b-catenin, cingulin, ZO-1, vinculin and b1 integrins) was
observed in the presence or absence of JAM-A (Figure S4B and C).
Interestingly,sectionsofmammaryglandsofJAM-A +/+ and 2/
2 mice presented partly disorganized E-cadherin staining suggest-
ing that, also in the absence of tumor, JAM-A expression is required
for a correct epithelial junction organization (Figure S5). TUNEL
staining was not significantly increased in normal JAM-A 2/2
mammary glands. Possibly, additional factors such as hypoxia may
contribute to tumor cell apoptosis in absence of JAM-A.
In a Ca
2+ switch assay the presence of BV11 mAb significantly
prolonged the time of junction recovery (complete recovery of E-
cadherin staining could be observed within 60 min in control
antibody treated cells while BV11 treated cells showed only partial
recovery up to 120 min) as reported [21] (Fig. 3C).
A further evidence of the role of JAM-A in the correct
organization of cell-to-cell junctions is given by the wound assay
(Fig. 3D). In this assay the weaker is cell-to-cell adhesion at
junctions, the higher is capacity of cells to migrate into the wound
[22]. As reported in the figure, when JAM-A was blocked by BV11
mAb cells migrate into the wound significantly more efficiently.
These data were further supported by in vivo observations. In
MMTV-PyVmT carcinomas (Fig. 4A) we found that JAM-A is
strongly decreased at the tumor invasive edge as compared to
tumor nodules (Fig. 4A, compare a and b). The decrease in JAM-A
and ZO-1 could be seen also in sparse/subconfluent cell cultures
as compared to confluent cells (Fig. 4D). Consistently, when cells
invade the surrounding tissue and junctions are partially
dismantled, JAM-A expression is significantly reduced.
We then asked whether there is a correlation between the effect of
JAM-A on junctions and its anti apoptotic activity. Invading tumor
cells in a wounded monolayer in vitro or at the invading edge of a
tumor in vivo were positive to TUNEL staining (Fig. 4B and C) This
marginal zone corresponds to the area where JAM-A is reduced.
Most importantly, the number of TUNEL positive cells was strongly
increased in JAM-A2/2tumor cells, not onlyat the leadingedge but
also in the more internal regions of the monolayer (Fig. 4D). In
contrastJAM+/+ cells were apoptotic only at the migrating rim while
in the internal regions of the monolayers, where JAM-A is correctly
expressed and organized at junctions, cells were TUNEL negative.
Thus, as previously described in other cell types [10,11,23],
JAM-A is required for correct junction organization in mammary
tumor cells. Stable junctions are known to protect the cells from
apoptotic stimuli [24], when JAM-A is reduced or junctions are
dismantled, as in migrating cells or in JAM-A null tumor cells,
apoptosis is increased.
Figure 5. Association of JAM-A expression and prognosis in clinical samples. A) A total 444 human breast cancer were examined. Scores
were evaluated on the level of JAM-A expression at cell membrane. Tumors were divided in JAM-A negative when no JAM-A was detected and JAM-A
positive when JAM-A staining, either complete or incomplete, was present on the membrane of more than 10% of tumor cells. Scale bar; 200 mm.
doi:10.1371/journal.pone.0021242.g005
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JAM-A+/+ mammary tumor and gene-set enrichment
analysis (GSEA)
To investigate the phenotype of JAM-A positive and null tumors
we compared gene profiles of early stages of MMTV-PyVmT/
JAM-A+/+ and JAM-A2/2 tumor extracts. We obtained a gene
list of total 547 differentially expressed genes (pset) (the ‘‘MMTV-
PyVmT/JAM-A2/2 signature’’) presented in Table S1 Sheet 1.
‘‘MMTV-PyVmT/JAMA2/2 signature’’ genes were classified by
functional and network annotation by Ingenuity Pathways Analysis
(IPA) program and top-ranked classification of the differentially
expressed genes was performed. The functional classification
indicates that genes involved in apoptosis, cell morphology, cell
growth and movement are grouped at the top of the list (Table S1,
Sheet 2 ‘‘Functional classification’’ and Sheet 3 ‘‘Network
Classification’’). We then analyzed GSEA by using MMTV-
PyVmT/JAM-A2/2 signature and G1–G3 human breast tumor
published data set derived from the studies of Ivshina et al [25].
Interestingly, from GSEA analysis we found that the genes over
expressed by MMTV-PyVmT/JAM-A+/+ mice tumors are also
over expressed in human G3 tumors, whereas genes over expressed
by JAM-A2/2 mice tumors are over expressed in human G1
tumors (Table S2, Sheet 1 ‘‘GSEA Dataset G3 vs G1’’ and Sheet 2
‘‘GSEA Dataset G3 vs G1 overlap’’).
JAM-A is a negative prognostic factor in human breast
tumor patients
Expression JAM-A was determined in a case-control study
composed of a total of 444 breast tumor samples, arrayed into 5
different TMAs (Table S3) [17]. We classified the tumors in two
major groups for expression of JAM-A: negative (tumors where
JAM-A is absent) versus positive (tumors with different degrees of
JAM-A expression (Fig. 5A). Clinico-pathological associations are
summarized in Table 1. JAM-A expression positively correlates
with tumor stage (p=0.002), nodal status (p=0.001), Elston
Grade (p=0.024) and Poor Prognosis Group according to the
Nottingham Prognostic Index (NPI) (p,0.001); Ductal Tumors
tend to form glandular structures, whereas lobular tumors are less
cohesive and invade in single file. In line with this notion, JAM-A
expression is frequently abrogated in Lobular Breast Carcinomas
in comparison to Ductal Carcinomas (p=0.007). In univariate
analysis, JAM-A expression significantly correlated with a higher
risk of developing a breast-related event (Table 2). However in a
multivariate analysis in which all events were evaluated in relation
to relevant prognostic factors, such as pathological stage, tumor
grade, estrogen receptor expression, nodal status, Ki67 and Her2/
Neu expression, JAM-A lost its predictive power (Table 2).
Discussion
The results presented here show that JAM-A is a negative
prognostic factor for murine and human mammary tumor growth.
This conclusion is supported by a different and complementary set
of results. In MMTV-PyVmT mammary tumor mouse model,
genetic ablation of JAM-A leads to a significant delay in tumor
appearance and growth. The number of metastasis tends to be
lower in absence of JAM-A, although the difference is not
significant (Fig. 1). Since the incidence of metastasis correlates with
tumor size, it is likely that the lower incidence of metastasis is a
consequence of a smaller tumor size.
In a previous work we found that the absence of JAM-A inhibited
the growth of Rip1Tag2 carcinoma[9]. This effectwas mediatedby
the immune reaction of the stroma since these particular tumor cells
do not express JAM-A. However, in MMTV-PyVmT tumor model
the immune and inflammatory cell infiltrate was very poor and, in
absence of JAM-A, we could not observe significant differences in
dendritic cell and monocyte infiltration. The number of infiltrating
CD4+ and CD8+ cells was increased in JAM-A null tumors but the
difference was not statistically significant. Overall, we cannot
exclude that the immune reaction may contribute to reduced tumor
Table 1. Correlation of JAM-A expression and
clinicopathological parameters in invasive breast carcinomas.
JAM_A NEG POS OR (C.I.) Pvalue
PATIENTS 273 135 (33.1%)
AGE
,50 126 70 (35.7%)
.=50 147 64 (30.3%) 0.784 ( 0.517–1.185 ) 0.249
HISTOTYPE
Ductal 216 120 (35.7%)
Lobular 51 11 (17.7%) 0.388 ( 0.186–0.747 ) 0.007
pT
1 162 59 (26.7%)
2–4 99 70 (41.4%) 1.941 ( 1.268–2.984 ) 0.002
LN
Neg 160 54 (25.2%)
Pos 113 80 (41.5%) 2.098 ( 1.381–3.207 ) 0.001
GRADE
G1 57 16 (21.9%)
G2 102 50 (32.8%) 1.417 ( 1.041–1.945 ) 0.093
G3 78 47 (37.6%) 2.009 ( 1.084–3.786 ) 0.024
ER
,10% 72 45 (38.5%)
.=10% 188 84 (30.9%) 0.715 ( 0.455–1.128 ) 0.146
PGR
,10% 99 62 (38.5%)
.=10% 155 67 (30.2%) 0.69 ( 0.45–1.059 ) 0.089
ERBB2
Neg 215 106 (33%)
Pos 32 24 (42.9%) 1.521 ( 0.847–2.705 ) 0.155
Ki67
,16% 122 55 (31.1%)
.=16% 132 74 (35.9%) 1.244 ( 0.812–1.911 ) 0.317
NPI
GPG 87 23 (20.9%)
MPG 91 46 (33.6%) 1.912 ( 1.079–3.459 ) 0.029
PPG 44 38 (46.3%) 3.267 ( 1.75–6.219 ) ,0.001
TMA (Immunohistochemical-Tissue Micro Array (IHC-TMA). Odds ratio (OR) and
95% Confidence Intervals (CI) were obtained from logistic regression models.
Note that the number of scored cases is lower that the total number of cases
since: i) in some cases, individual cores detached from the slides during the
manipulations; ii) clinical information was not available for all patients. In tumor
tissues the IHC signals were associated with the tumor cell component and not
with the adjacent or infiltrating stroma. Nottingham Prognostic Index (NPI)
combines nodal status, tumor size and histological grade. According to NPI’s
score patients can be divided into 3 class: Good Prognosis Group (GPG),
Moderate Prognosis Group (MPG) and Poor Prognosis Group (PPG). Primary
tumor size according to the TNM staging system, pT; Estrogen receptor, ER;
Progesterone receptor, PGR. LN: Lymph Node status.
doi:10.1371/journal.pone.0021242.t001
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this effect the observed reduction in tumor size. In contrast to
Rip1Tag2, MMTV-PyVmT tumor cells are positive for JAM-A.
Normal mammary gland and ductal epithelium express relatively
high amounts of JAM-A (Figure S1) which is maintained high in
tumor cells. We found that in MMTV-PyVmT/JAM-A2/2
tumors and tumor cells derived from them, apoptosis was markedly
increased. The anti apoptotic effect of JAM-A was also apparent in
themouse breast tumor cell line 4T1when JAM-Awasblocked by a
specific antibody.
An important issue is the definition of the mechanism of action
of JAM-A in protecting tumor cells from apoptosis. A correct
organization of cell to cell junctions induces cell resistance to
apoptotic stimuli through activation of different pathways
[24,26,27], therefore agents able to dismantle intercellular
junctions increase cell sensitivity to apoptosis. We report that
JAM-A disrupts junction architecture. Furthermore, apoptosis was
increased at the JAM-A+/+ tumor invasive front in vivo where
JAM-A expression is also decreased. Consistently, genetic ablation
of JAM-A increased apoptosis not only at the invasive front but
also diffusely in all tumor cells.
The block of JAM-A decreases 4T1 cell number at 48 hours
when the difference in apoptosis is still undetectable. The
reduction in cell number is apparent only in absence of serum
but not when cells are grown in complete medium (Fig. 2B and C).
This suggests that inhibition of JAM-A may reduce cell growth
when cells are in starvation.
However, since at 48 hours of starvation cells also show signs of
partial retraction we cannot exclude that the observed reduction in
cell number is due to cell detachment. Other authors have shown
that, when JAM-A expression or activity is reduced in cultured
mammary tumor [10] and renal carcinoma cells [20], the cells
detach more easily from a monolayer and migrate more efficiently.
These observations have been interpreted as increased tumor cell
invasive and metastatic capacity but direct in vivo data in
preclinical models have not been reported in these papers. As
shown here the lack of JAM-A and the consequent alterations in
junction organization leads to increased cell migration but also
sensitivity to apoptosis. The final balance of these two aspects of
JAM-A activity may determine the overall tumor cell dissemina-
tion in vivo.
In the epithelium of the mouse mucosa abrogation of JAM-A
expression increased permeability and cell sensitivity to pro
apoptotic inflammatory stimuli. In these cells the absence of
JAM-A did not severely affect junctions organization in normal
conditions but exacerbated the effects of inflammatory agents in
bowel disease [7,8]. As reported here, in normal mammary glands
and more dramatically in breast cancer cells, in absence of JAM-A,
junctions were altered. Cancer cell junctions are relatively poorly
organized and it is not surprising that the decrease/abrogation of
expression of a junctional component, such as JAM-A, induces
more dramatic effects than in normal epithelial cells.
The data presented here using a preclinical model are consistent
with the results obtained by TMA analysis of a group of 444
patients’ specimens. Through this analysis we found a significant
correlation between JAM-A expression and a poor tumor
prognosis. McSherry et al. [11] observed a similar type of
correlation in a group of 270 patients with invasive breast cancer,
while Naik et al. [10] found an opposite correlation between JAM-
A expression and tumor invasion in 12 tumors and their
corresponding non neoplastic tissue as well as 50 malignant and
their corresponding metastatic lymph node samples. Taking into
consideration the larger data set of McSherry et al. [11], the
present work (270 and 444 patients respectively) and the
association of clinicopathological data, we feel rather confident
that in a majority of cases high JAM-A expression is a prognostic
factor of a poor patient outcome.
A further support to this conclusion comes from GSEA.
Comparison of gene expression profiles of JAM-A+/+ and 2/2
tumors and the G1–G3 human breast tumor published data [25]
shows that genes over expressed by MMTV-PyVmT/JAM-A+/+
mice tumors are also over expressed in human G3 tumors,
whereas genes over expressed by JAM-A2/2 mice tumors are
over expressed in human G1 tumors. This analysis further
supports the concept that JAM-A expression is associated with a
‘‘poor prognosis signature’’. Interestingly, essentially no overlap-
ping between G1 and G3 genes was observed comparing JAM-
A+/+ and 2/2 tumors.
McSherry et al. [11,28] and Gotte et al. [29] found that
mammary tumor cell lines have a reduced motility when JAM-A is
low and this effect was attributed to a lower expression of b1
integrins [11,28]. Integrins can also transfer anti apoptotic signals
and we cannot exclude that changes in b1 integrin expression
could further contribute to JAM-A mediated anti apoptotic
activity. In the present work in both MMTV-PyVmT derived
tumor cells or 4T1 cell lines we observed increased and not
decreased migration and we did not detect a significant change in
b1 expression levels (Figure S4B). This discrepancy may be easily
attributed to the different cell lines used and, possibly, to a
different set of integrins expressed [18,19,22].
In conclusion, in vitro and in vivo data, using a genetic mammary
tumor model or analyzing a large group of patient specimens, are
Table 2. Univariate and multivariate analyses of JAM-A expression in breast cancer case-control datasets.
CASE-CONTROL COHORT (N=444)
ALL EVENTS Univariate Multivariate
*OR (95% CI) P *OR (95% CI) P
JAM-A Pos. vs. Neg. 1.593 (1.05–2.42) 0.028 1.474 ( 0.81–2.69 ) 0.205
DISTANT EVENTS Univariate Multivariate
*OR (95% CI) P *OR (95% CI) P
JAM-A Pos. vs. Neg. 1.416 (0.86–2.31) 0.165 1.557 ( 0.76–3.19 ) 0.224
All events, loco-regional relapse, distant metastasis or controlateral breast cancer; distant events, distant metastasis. Odds ratio (OR) and 95% Confidence Intervals (CI)
were obtained from logistic regression models and adjusted for age, pathological stage, histotype, tumor grade, hormone-receptor status, nodal status, Ki-67, NPI and
ErbB2 expression in the multivariate analysis.
doi:10.1371/journal.pone.0021242.t002
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in breast cancer. We propose that this effect is due, at least in part,
to the protective effect of JAM-A on tumor cell apoptosis and is
likely correlated to disruption of a correct junction organization.
The mechanisms through which tumor cells maintain high JAM-A
during tumor progression remains to be defined. However, a
recent publication [29] shows that JAM-A is a target for miR-145
which, in turn, is downregulated in breast cancer cells. These data
may, therefore, explain the high levels of JAM-A in this particular
type of tumor.
Supporting Information
Figure S1 JAM-A is expressed both in wild type and
MMTV-PyVmT mice mammary tumors by immunohis-
tological analysis of tissue samples. (A) JAM-A is expressed
in epithelial of JAM-A +/+ mammary gland mice (left panel) and
not in that of JAM-A 2/2 mice (right panel). Scale bar 200 mm.
(B) JAM-A is expressed in epithelial of normal mammary gland
(left panel) and MMTV mammary tumor (right panel). Scale bar
100 mm. (C) JAM-A is expressed in primary mammary tumor,
metastatic lymph nodes and metastatic lung tumor. Scale bar
400 mm.
(TIF)
Figure S2 Mammary tumor weight positively correlates
with lung metastasis in MMTV-PyVmT mice, but JAM-A
expression does not affect this parameter. Relationship
between primary mammary tumor size and lung metastases of
MMTV mice with or without JAM-A. Primary mammary tumor
weight and lung metastases are positively correlated both in
MMTV-PyVmT/JAM-A+/+ and in MMTV-PyVmT/JAM-A2/
2 mice but the lung metastatic ratio show no significant difference
between these groups.
(TIF)
Figure S3 Immunohistological analysis of MMTV-
PyVmT/JAM-A2/2 or JAM-A+/+ tumors. A) Vascular
density evaluated by PECAM-1 staining of vessels was not
significantly different in JAM-A +/+ and 2/2 tumors
(4625262776 versus 4983864311 mm
2/mm
2 p=0.488; means
6 SEM) Scale bar; 100 mm. B) No significant difference were
observed in infiltration of CD11c- and MHC-II-positive dendritic
cells, F4/80-positive macrophages and CD4- and CD8-positive
leukocytes in MMTV-PyVmT/JAM+/+ or 2/2 tumors.
(CD11c-positive cells, 723649.33 vs 674.47649.08 cells per
mm
2 p=0.489; MHC-II-positive cells 417.8631.12 vs
423.73648.03 cells per mm
2 p=0.918; F4/80-positive cells
643.73643.61 vs 669.27642.40 cells per mm
2 p=0.677; CD4-
positive cells 46.265.84 vs 64.868.58 cells per mm
2 p=0.080;
CD8-positive cells 20.3363.60 vs 28.8764.69 cells per mm
2
p=0.156. Data represent means 6 SEM).
(TIF)
Figure S4 Characterization of mammary cells. A) JAM-A
expression in 4T1 cells by Western blot analysis. Data show that
4T1 cells express a comparable level of JAM-A as compared to
wild type endothelial cells (EC). The specificity of the Ab (BV11)
was indicated by lack of staining of EC from JAM-A2/2 mice
[18]. B) Western blot analysis shows that cultured MMTV-
PyVmT/JAM-A+/+ mammary tumor cells express JAM-A in
sparse and confluent conditions. As expected, JAM-A staining was
absent in cells derived from tumors of JAM-A null mice. Integrin
b1 chain or E-cadherin were not significantly changed in the
presence or absence of JAM-A.
(TIF)
Figure S5 Inhibition of JAM-A expression affects the
organization of cell-cell junctions of mammary gland, but
does not affect apoptosis. A) Immunofluorescence staining of
E-cadherin and TUNEL. While in JAM-A+/+ mammary glands
epithelial cells present a continuous junctional staining of E-
cadherin at intercellular contacts (a, a0), in JAM-A2/2 mammary
glands the distribution of this marker was more discontinuous (b,
b0). No differences of the TUNEL staining have been observed (a9,
b9). Scale bars: 100 mm (a, a9,b, b9)a n d1 0mm( a 0,b 0).
(TIF)
Table S1 Characterization of MMTV-PyVmT JAM-A2/
2 signature. ‘‘MMTV-PyVmT JAM-A-signature’’ sheet: This
file lists the probesets of the MMTV-PyVmT/JAM-A2/2
signature. For each entry, the following information is reported
(from left to right): (1) probeset (corresponding to the detecting
probeset on Affymetrix GENE 1.0 ST Mouse GeneChips), (2)
GenBank accession number of the corresponding gene, (3) Gene
Symbol, (4) regulation, the criteria to designate a probeset as
JamA2 (MMTV-PyVmT/JAM-A2/2) up or down versus
JamA+ (MMTV-PyVmT/JAM-A+/+). Genes were considered
upregulated (upregulated in MMTV-PyVmT/JAM-A2/2, high-
lighted in red) or downregulated (upregulated in MMTV-
PyVmT/JAM-A+/+, highlighted in green), (5) FC (fold-change)
in the JamA-/JamA+ comparison, across all samples, (6) P-value of
FC in the JamA-/JamA+, (7) Description of gene. ‘‘Functional
classification’’ sheet: This file reports the functional annotation of
genes of the MMTV-PyVmT JAM-A-signature. ‘‘Network
classification’’ sheet: This file reports the network annotation of
genes of the MMTV-PyVmT JAM-A-signature.
(XLS)
Table S2 ‘‘GSEA Dataset G3 vs G1’’ sheet: Genes of the
overlap between MMTV-PyVmT JAM-A-signature and
enriched genes in G3 versus G1 tumors of Ivshina data
set. For each entry, the following information is reported (from
left to right): (1) Mouse Gene Symbol from MMTV-PyVmT
JAM-A- signature, (2) GenBank accession number of the
corresponding gene, (3) Ratio in the JamA-/JamA+,( 4 )F C
(fold-change) in the JamA2/JamA+ comparison, (5) P-value of
FC in the JamA2/JamA+ (6) Human Symbol (Ivshina data set
corresponding to the detecting probeset on Affymetrix GENE 1.0
ST Mouse GeneChips) (7) U133 Probe Set (of Ivshina affimetrix
HG-U133 Human GeneChips), (8) GSEA ENRICHMENT,
genes with a ‘‘Yes HIGH in G1’’ gene in high expression in G1
breast tumor or a ‘‘Yes HIGH in G3’’ gene in high expression in
G3 breast tumor. ‘‘GSEA Dataset G3 vs G1 overlap’’ sheet:
Selected from overlap genes between MMTV-PyVmT JAM-A-
signature and G3 or G1 upregulated genes from sheet ‘‘GSEA
Dataset G3 vs G1’’.
(XLS)
Table S3 Clinical and pathological information of the
case-control dataset of breast cancer patients. The
clinical and pathological information of the patients of the case-
control dataset is reported. Disease recurrence (all events and
distant events) was within 7 years. For some patients not all
information was available. Nottingham Prognostic Index (NPI)
combines nodal status, tumor size and histological grade.
According to NPI’s score patients can be divided into 3 classes:
Good Prognosis Group (GPG), Moderate Prognosis Group
(MPG) and Poor Prognosis Group (PPG). Primary tumor size
of WHO classification, pT; Estrogen receptor, ER; Progesterone
receptor, PGR.
(DOC)
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